LimmaTech Biologics
Clinical-stage biotechnology company developing innovative vaccines and biologics for infectious diseases and difficult-to-treat cancers.
Website
https://www.limmatech.comLocation
Basel, Switzerland
Founded
2010
Investors
1
Categories
biotech, vaccines, infectious-disease, biologics, therapeutics
Notes
LimmaTech Biologics is a clinical-stage biotechnology company focused on developing novel vaccines and biologics to prevent and treat infectious diseases and cancer. The company leverages its proprietary glycoengineering and bioconjugate platform technologies to create next-generation vaccines.
Based in Basel, Switzerland, LimmaTech is developing therapies targeting bacterial infections, including those caused by antimicrobial-resistant pathogens, as well as oncology applications.
Team
- Information on leadership team pending further research
Additional Research Findings
- Founded in 2010
- Headquartered in Basel, Switzerland
- Portfolio company of Adjuvant Capital
- Proprietary glycoengineering platform
- Focus on bacterial vaccines and oncology
- Addressing antimicrobial resistance challenges
- Bioconjugate technology platform
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Adjuvant Capital | Washington, DC, USA | biotech-focused | seedseries-a+3 | 16 |